Vessel Fractional Flow Reserve and Graft Vasculopathy in Heart Transplant Recipients.


Journal

Journal of interventional cardiology
ISSN: 1540-8183
Titre abrégé: J Interv Cardiol
Pays: United States
ID NLM: 8907826

Informations de publication

Date de publication:
2020
Historique:
received: 17 02 2020
accepted: 12 05 2020
entrez: 1 8 2020
pubmed: 1 8 2020
medline: 1 12 2020
Statut: epublish

Résumé

Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after heart transplantation (HTx). The severity and extent of CAV is graded with conventional coronary angiography (COR) which has several limitations. Recently, vessel fractional flow reserve (vFFR) derived from COR has emerged as a diagnostic computational tool to quantify the functional severity of coronary artery disease. The present study assessed the usefulness of vFFR to detect CAV in HTx recipients. In HTx patients referred for annual check-up, undergoing surveillance COR, the extent of CAV was graded according to the criteria proposed by the international society of heart and lung transplantation (ISHLT). In addition, three-dimensional coronary geometries were constructed from COR to calculate pressure losses using vFFR. In 65 HTx patients with a mean age of 53.7 ± 10.1 years, 8.5 years (IQR 1.90, 15.2) years after HTx, a total number of 173 vessels (59 LAD, 61 LCX, and 53 RCA) were analyzed. The mean vFFR was 0.84 ± 0.15 and median was 0.88 (IQR 0.79, 0.94). A vFFR ≤ 0.80 was present in 24 patients (48 vessels). HTx patients with a history of ischemic cardiomyopathy (ICMP) had numerically lower vFFR as compared to those with non-ICMP (0.70 ± 0.22 vs. 0.79 ± 0.13, The impairment in epicardial conductance assessed by vFFR in a subgroup of patients without CAV according to standard ISHLT criteria suggests the presence of a diffuse vasculopathy undetectable by conventional angiography. Therefore, we speculate that vFFR may be useful in risk stratification after HTx.

Sections du résumé

BACKGROUND BACKGROUND
Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after heart transplantation (HTx). The severity and extent of CAV is graded with conventional coronary angiography (COR) which has several limitations. Recently, vessel fractional flow reserve (vFFR) derived from COR has emerged as a diagnostic computational tool to quantify the functional severity of coronary artery disease.
PURPOSE OBJECTIVE
The present study assessed the usefulness of vFFR to detect CAV in HTx recipients.
METHODS METHODS
In HTx patients referred for annual check-up, undergoing surveillance COR, the extent of CAV was graded according to the criteria proposed by the international society of heart and lung transplantation (ISHLT). In addition, three-dimensional coronary geometries were constructed from COR to calculate pressure losses using vFFR.
RESULTS RESULTS
In 65 HTx patients with a mean age of 53.7 ± 10.1 years, 8.5 years (IQR 1.90, 15.2) years after HTx, a total number of 173 vessels (59 LAD, 61 LCX, and 53 RCA) were analyzed. The mean vFFR was 0.84 ± 0.15 and median was 0.88 (IQR 0.79, 0.94). A vFFR ≤ 0.80 was present in 24 patients (48 vessels). HTx patients with a history of ischemic cardiomyopathy (ICMP) had numerically lower vFFR as compared to those with non-ICMP (0.70 ± 0.22 vs. 0.79 ± 0.13,
CONCLUSION CONCLUSIONS
The impairment in epicardial conductance assessed by vFFR in a subgroup of patients without CAV according to standard ISHLT criteria suggests the presence of a diffuse vasculopathy undetectable by conventional angiography. Therefore, we speculate that vFFR may be useful in risk stratification after HTx.

Identifiants

pubmed: 32733172
doi: 10.1155/2020/9835151
pmc: PMC7376430
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9835151

Informations de copyright

Copyright © 2020 Sakura Nagumo et al.

Déclaration de conflit d'intérêts

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Références

J Heart Lung Transplant. 2010 Jul;29(7):717-27
pubmed: 20620917
J Am Coll Cardiol. 2017 May 2;69(17):2212-2241
pubmed: 28291663
Eur Heart J. 2018 Sep 14;39(35):3314-3321
pubmed: 30137305
Transpl Int. 2010 Nov;23(11):1094-104
pubmed: 20477994
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
EuroIntervention. 2017 Aug 25;13(6):634-643
pubmed: 28844026
Am J Cardiol. 2007 Jun 1;99(11):1603-7
pubmed: 17531589
JACC Heart Fail. 2017 Dec;5(12):891-901
pubmed: 29191295
Eur Heart J. 2014 Oct 1;35(37):2541-619
pubmed: 25173339
Circulation. 2016 May 17;133(20):1945-50
pubmed: 27143679
EuroIntervention. 2019 May 14;:
pubmed: 31085504
Transplantation. 1996 Jan 15;61(1):46-53
pubmed: 8560573
Circulation. 2003 Sep 30;108(13):1605-10
pubmed: 12963639
J Am Coll Cardiol. 2016 Jul 5;68(1):80-91
pubmed: 27364054
Circulation. 1992 Mar;85(3):979-87
pubmed: 1537134
J Am Coll Cardiol. 1986 Jan;7(1):103-13
pubmed: 3941196
Catheter Cardiovasc Interv. 2018 Dec 1;92(7):E527-E536
pubmed: 30265435
Chest. 2000 Dec;118(6):1792-800
pubmed: 11115475
Circulation. 2001 Aug 7;104(6):653-7
pubmed: 11489770
J Cardiovasc Transl Res. 2013 Apr;6(2):263-77
pubmed: 23135991
J Heart Lung Transplant. 2006 Jul;25(7):765-71
pubmed: 16818118
N Engl J Med. 2009 Jan 15;360(3):213-24
pubmed: 19144937

Auteurs

Sakura Nagumo (S)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.
Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, 2278501 Kanagawa, Japan.

Emanuele Gallinoro (E)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.

Alessandro Candreva (A)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Takuya Mizukami (T)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.
Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, 2278501 Kanagawa, Japan.

Giovanni Monizzi (G)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Monika Kodeboina (M)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.
Department of Advanced Biomedical Sciences, Federico II University, 80131 Naples, Italy.

Sofie Verstreken (S)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Riet Dierckx (R)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Ward Heggermont (W)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.
Cardiovascular Research Center Maastricht, Maastricht, AZ-6202, Netherlands.

Jozef Bartunek (J)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Marc Goethals (M)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Dimitri Buytaert (D)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Bernard De Bruyne (B)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.
Department of Cardiology, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Jeroen Sonck (J)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.
Department of Advanced Biomedical Sciences, Federico II University, 80131 Naples, Italy.

Carlos Collet (C)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Marc Vanderheyden (M)

Cardiovascular Center Aalst, OLV Clinic, 9300 Aalst, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH